EyePoint tumbles 30% premarket on failed Phase 2 study (NASDAQ:EYPT)

Published on 6 May 2024 on Seeking Alpha

EyePoint (EYPT) stock tumbled nearly 30% in premarket trading Monday after the company said a Phase...

Read the rest of the article

Start tracking your investments with Statfolio

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) shareholders should be happy to see the share price ...

Simply Wall St. · via Yahoo Finance 25 Jan 2025

On May 14, 2024, David Guyer, Director at EyePoint Pharmaceuticals Inc (NASDAQ:EYPT), executed a ...

GuruFocus.com via Yahoo Finance 16 May 2024

Tuesday, Mizuho adjusted its outlook on EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), slashing th...

Investing.com 7 May 2024

U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining more than 1...

Benzinga 6 May 2024

EyePoint Pharmaceuticals, Inc. (NASDAQ: NASDAQ:EYPT) announced interim results from its Phase 2...

Investing.com 6 May 2024

U.S. stocks were higher, with the Nasdaq Composite gaining over 100 points on Monday. Shares of S...

Benzinga 6 May 2024

Shares of Perficient, Inc PRFT shares rose sharply during Monday's session after the company disc...

Benzinga 6 May 2024

Why Is EyePoint Pharmaceuticals Stock Plummeting On Monday? On Monday, EyePoint Pharmaceuticals I...

Benzinga via Yahoo Finance 6 May 2024

dropped nearly 30% in premarket trading Monday after the company said its experimental...

Market Watch 6 May 2024

EyePoint (EYPT) stock tumbled nearly 30% in premarket trading Monday after the company said a Pha...

Seeking Alpha 6 May 2024